Myriad has failed to stop Ambry offering genetic tests using the BRCA1 or BRCA2 genes, but Ambry raised a substantial question about the validity of the claims of Myriad’s patents, as MaryAnne Armstrong reports.
Apexigen uses antibodies derived from rabbits to develop therapies for diseases that are difficult to treat. LSIPR found out how it protects its novel technologies.
The US Supreme Court has again reversed a Federal Circuit decision, this time over burden of proof, says Matthew Nielsen.
In a global league, Canada’s biotech industry would be respectably mid table. LSIPR talks to Andrew Casey, president of industry association BIOTECanada, about how the organisation is trying to take it to the next level.
Stem cells are seen by many as the great hope for medical research in the years to come. LSIPR spoke to Nicholas Seay, chief technology officer at Cellular Dynamics, about the importance of IP in this field.
How can ‘big’ data help drug candidates through the pipeline? And who does the data belong to? LSIPR spoke to NuMedii chief executive Gini Deshpande.
The first US court decision applying the Myriad decision has landed, and it makes for interesting reading, as Antoinette Konski reports.
New guidelines for the examination of biotechnology inventions in Brazil provide useful support for applicants, as Gabriel Di Blasi and Alexandre Santos explain.
In Mexico, it can be tricky to protect data exclusivity, but prospective international agreements may provide a solution, as Jose Trigueros explains.
In the life sciences sector, defending broad patent claims can be a tricky business, says Gordon Wright.